

Requested by Representative BUEHLER

**PROPOSED AMENDMENTS TO  
HOUSE BILL 2645**

1 On page 1 of the printed bill, delete lines 4 through 28 and delete pages  
2 2 through 10 and insert:

3 **“SECTION 1. (1) As used in this section:**

4 **“(a) ‘Hospital’ has the meaning given that term in ORS 442.015.**

5 **“(b) ‘Law enforcement agency’ means an agency that employs law  
6 enforcement officers to enforce criminal laws.**

7 **“(c) ‘Law enforcement officer’ means an officer employed to enforce  
8 criminal laws by:**

9 **“(A) This state or a municipal government within this state; or**

10 **“(B) A political subdivision or agency of a government described in  
11 subparagraph (A) of this paragraph.**

12 **“(d)(A) ‘Manufacturer’ means:**

13 **“(i) A manufacturer, as defined in ORS 689.005, that manufactures  
14 drugs that are sold within this state; or**

15 **“(ii) A pharmacy benefit manager, as defined in ORS 735.530.**

16 **“(B) ‘Manufacturer’ does not include a person who:**

17 **“(i) Packages or repackages prescription drugs that are sold within  
18 this state or who labels or relabels the containers of prescription drugs  
19 that are sold within this state; and**

20 **“(ii) Does not produce, prepare, propagate, compound, convert or  
21 process prescription drugs that are sold within this state.**

1       “(e) ‘Retail drug outlet’ has the meaning given that term in ORS  
2       689.005.

3       “(2)(a) The Public Health Director and the State Board of Pharmacy  
4       shall collaborate to establish a program under which the Oregon  
5       Health Authority and the board oversee the establishment of kiosks  
6       in this state for the purpose of collecting from consumers and disposing  
7       of the following drugs:

8       “(A) Prescription drugs, as defined in ORS 689.005;

9       “(B) Nonprescription drugs, as defined in ORS 689.005;

10       “(C) Drugs marketed under a brand name, as defined in ORS  
11       689.515;

12       “(D) Drugs marketed under a generic name, as defined in ORS  
13       689.515;

14       “(E) Biological products, as described in ORS 689.522;

15       “(F) Drugs intended to be used by a licensed veterinarian; and

16       “(G) Combination products.

17       “(b) This subsection does not require the authority or the board,  
18       or any entity described in subsection (3)(a) of this section, to use  
19       kiosks for the purpose of collecting from consumers and disposing of:

20       “(A) Vitamins or supplements;

21       “(B) Herb-based remedies or homeopathic drugs, products or reme-  
22       dies;

23       “(C) Products that are regulated as both a cosmetic and a  
24       nonprescription drug by the federal Food and Drug Administration;

25       “(D) Drugs and biological products for which a manufacturer ad-  
26       ministers a drug take-back program as part of a risk evaluation and  
27       mitigation strategy under the oversight of the federal Food and Drug  
28       Administration; or

29       “(E) Pet pesticide products.

30       “(3) In establishing the program described in subsection (2) of this

1 section, the director and the board shall:

2 “(a) Collaborate with hospitals, retail drug outlets and law  
3 enforcement agencies to establish new kiosks and enhance existing  
4 kiosks on the premises of those entities for the purpose of collecting  
5 from consumers and disposing of the drugs described in subsection  
6 (2)(a) of this section;

7 “(b) Ensure that each kiosk established pursuant to paragraph (a)  
8 of this subsection is located on the premises of a hospital, retail drug  
9 outlet or law enforcement agency that qualifies under federal law to  
10 collect and dispose of controlled substances;

11 “(c) Ensure that at least one kiosk is established pursuant to par-  
12 agraph (a) of this subsection at each retail drug outlet located within  
13 a hospital or within a health care facility owned by a hospital;

14 “(d) Work toward establishing at least one kiosk pursuant to para-  
15 graph (a) of this subsection for every 20,000 residents of this state;

16 “(e) In consultation with the Department of Environmental Quality,  
17 provide for the safe disposal of drugs collected at kiosks established  
18 pursuant to paragraph (a) of this subsection;

19 “(f) Compile information on:

20 “(A) How to properly dispose of drugs described in subsection (2)(a)  
21 of this section in accordance with applicable federal laws and regu-  
22 lations;

23 “(B) The location of kiosks established pursuant to paragraph (a)  
24 of this subsection; and

25 “(C) How to properly use kiosks established pursuant to paragraph  
26 (a) of this subsection;

27 “(g) Prepare print publications of the information described in par-  
28 agraph (f) of this subsection; and

29 “(h) Distribute the print publications described in paragraph (g) of  
30 this subsection to retail drug outlets for the purpose of being dissem-

1 inated to the public.

2 “(4)(a) The authority shall impose an annual fee against manufac-  
3 turers for the purpose of paying the costs associated with compiling,  
4 preparing print publications for and disseminating information as re-  
5 quired by subsection (3)(f), (g) and (h) of this section. The authority  
6 may impose and collect the fee in a manner prescribed by the au-  
7 thority, provided that the fee is based on the volume of prescription  
8 drugs sold by the manufacturer in this state.

9 “(b) Except as provided in paragraph (c) of this subsection, fee  
10 moneys collected by the authority under this subsection must be de-  
11 posited in the Oregon Health Authority Fund established under ORS  
12 413.101. Fee moneys deposited in the fund under this paragraph are  
13 continuously appropriated to the authority for purposes of adminis-  
14 tering this section.

15 “(c) As deemed necessary by the authority and the board to pay the  
16 board’s costs incurred under this section, the authority shall transfer  
17 a portion of the fee moneys collected by the authority under this  
18 subsection to the board for deposit in the State Board of Pharmacy  
19 Account established under ORS 689.139. Fee moneys deposited in the  
20 account under this paragraph are continuously appropriated to the  
21 board for purposes of administering this section.

22 “(5) The cost associated with establishing a new kiosk or enhancing  
23 an existing kiosk as required by subsection (3)(a) of this section shall  
24 be borne by the hospital, retail drug outlet or law enforcement agency  
25 where the kiosk is located.

26 “(6) The board, in consultation with the director, shall adopt rules  
27 necessary to implement this section.

28 **“SECTION 2. (1) This section is intended to establish that the state**  
29 **has the exclusive right to regulate the collection from consumers and**  
30 **disposal of the drugs described in section 1 (2)(a) of this 2017 Act.**

1       “(2) Except as otherwise expressly authorized by the laws of this  
2 state, a county or city, or other unit of local government, may not  
3 adopt an ordinance or rule that provides for the collection from con-  
4 sumers or disposal of the drugs described in section 1 (2)(a) of this 2017  
5 Act, except to the extent that the ordinance or rule provides for the  
6 enforcement of a state law or rule or federal law or regulation that  
7 governs the collection from consumers and disposal of the drugs de-  
8 scribed in section 1 (2)(a) of this 2017 Act.

9       “SECTION 3. (1) Section 1 of this 2017 Act becomes operative on  
10 January 1, 2018.

11       “(2) The Public Health Director, the Oregon Health Authority and  
12 the State Board of Pharmacy may take any action before the operative  
13 date specified in subsection (1) of this section that is necessary to en-  
14 able the director, the authority and the board to exercise, on and after  
15 the operative date specified in subsection (1) of this section, all the  
16 duties, functions and powers conferred on the director, the authority  
17 and the board by section 1 of this 2017 Act.

18       “SECTION 4. This 2017 Act takes effect on the 91st day after the  
19 date on which the 2017 regular session of the Seventy-ninth Legislative  
20 Assembly adjourns sine die.”.

21

---